Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (se deschide o fereastră nouă)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Sursă‎: Cancer 2013;119(21):3784-7.

Index‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (se deschide o fereastră nouă)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (se deschide o fereastră nouă)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Sursă‎: Lancet 1989;334(8655):122-4.

Index‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (se deschide o fereastră nouă)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (se deschide o fereastră nouă)

Ben-Bassat I, Douer D, Ramot B.

Sursă‎: Eur J Haematol 1990;45(2):86-9.

Index‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (se deschide o fereastră nouă)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (se deschide o fereastră nouă)

Dean A, Tuffin P.

Sursă‎: J Pain Symptom Manage 1997;13(1):20-4.

Index‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (se deschide o fereastră nouă)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (se deschide o fereastră nouă)

Ford PA, Grant SJ, Mick R, Keck G.

Sursă‎: J Clin Oncol 2015;33(15):1674-9.

Index‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (se deschide o fereastră nouă)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (se deschide o fereastră nouă)

Garewal HS, Durie BG.

Sursă‎: Scand J Haematol 1985;35(5):497-500.

Index‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (se deschide o fereastră nouă)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (se deschide o fereastră nouă)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Sursă‎: Cancer 2006;107(1):136-40.

Index‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (se deschide o fereastră nouă)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (se deschide o fereastră nouă)

Marshall A, Li A, Drucker A, Dzik W.

Sursă‎: Hematol Oncol 2016;34(3):147-53.

Index‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (se deschide o fereastră nouă)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (se deschide o fereastră nouă)

Prokopchuk-Gauk O, Brose K.

Sursă‎: Cureus 2015;7(12):e428.

Index‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (se deschide o fereastră nouă)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (se deschide o fereastră nouă)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Sursă‎: Leuk Lymphoma 1995;19(1-2):141-4.

Index‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (se deschide o fereastră nouă)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (se deschide o fereastră nouă)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Sursă‎: Hematol Oncol 2008;26(4):241-6.

Index‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (se deschide o fereastră nouă)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (se deschide o fereastră nouă)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Sursă‎: Am J Hematol 2006;81(9):720.

Index‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (se deschide o fereastră nouă)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (se deschide o fereastră nouă)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Sursă‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Index‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (se deschide o fereastră nouă)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (se deschide o fereastră nouă)

Erduran E, Bahadir A, Mutlu M.

Sursă‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Index‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (se deschide o fereastră nouă)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (se deschide o fereastră nouă)

Franchini M, Veneri D, Lippi G.

Sursă‎: Bone Marrow Transplant 2007;39(12):729-35.

Index‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (se deschide o fereastră nouă)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (se deschide o fereastră nouă)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Sursă‎: Am J Hematol 2002;69(3):219-22.

Index‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (se deschide o fereastră nouă)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (se deschide o fereastră nouă)

Hsieh A, Cheong I.

Sursă‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Index‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (se deschide o fereastră nouă)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (se deschide o fereastră nouă)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Sursă‎: Haemostasis 1996;26 Suppl 1:159-64.

Index‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (se deschide o fereastră nouă)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (se deschide o fereastră nouă)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Sursă‎: Med Oncol 2010;27(1):16-9.

Index‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (se deschide o fereastră nouă)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (se deschide o fereastră nouă)

Vidarsson B, Önundarson PT.

Sursă‎: Thromb Haemost 2000;83(4):634-5.

Index‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (se deschide o fereastră nouă)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (se deschide o fereastră nouă)

Zver S, Andoljšek D, Černelč P.

Sursă‎: Eur J Haematol 2004;72(6):455-6.

Index‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (se deschide o fereastră nouă)

Management of bleeding complications of hematologic malignancies. (se deschide o fereastră nouă)

Green D.

Sursă‎: Semin Thromb Hemost 2007;33(4):427-34.

Index‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (se deschide o fereastră nouă)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (se deschide o fereastră nouă)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Sursă‎: Int J Lab Hematol 2013;35(4):457-9.

Index‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (se deschide o fereastră nouă)

Management of bleeding in patients with advanced cancer. (se deschide o fereastră nouă)

Pereira J, Phan T.

Sursă‎: Oncologist 2004;9(5):561-70.

Index‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (se deschide o fereastră nouă)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (se deschide o fereastră nouă)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Sursă‎: Haematologica 1997;82(5):584-7.

Index‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (se deschide o fereastră nouă)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (se deschide o fereastră nouă)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Sursă‎: Bull Cancer 2006;93(2):E7-12.

Index‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (se deschide o fereastră nouă)